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Transcription, the first step of gene expression, is a process fundamental to all known 
forms of life. In eukaryotic cells, the enzyme RNA polymerase II (Pol II) executes 
transcription by moving forward along the DNA and transferring the encoded genetic 
information to messenger RNA. However, Pol II also backtracks on the DNA, causing 
transcription to become arrested. When backtracking occurs, Pol II slides backwards on 
the DNA, displacing nascent RNA from the active site into a proposed “backtrack site,” 
comprising residues in the Pol II subunits Rpb1 and Rpb2 that interact with the RNA. 
The resulting stable “arrested complex” must be reactivated for elongation to continue. 
While backtracking has been implicated in numerous processes essential for regulating 
gene transcription, its physiological relevance is not yet certain. Using Saccharomyces 
cerevisiae (Baker’s yeast), we have engineered individual and combinations of mutations 
in the Rpb1 region of the backtrack site to disrupt the protein-RNA interactions that arise 
from backtracking. Through phenotypic and growth comparisons between wild-type and 
mutant strains, we examine how impairing the binding of RNA to the backtrack site 
affects yeast fitness and various Pol II functions in vivo, providing further insight into the 
possible functions of Pol II during backtracking and arrest.  
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INTRODUCTION 
Gene expression is fundamental to all known forms of life, from simple bacteria to 
complex multicellular organisms like humans. When genes are expressed, the instructions 
encoded in DNA are converted to a biologically functional product. This product, 
generally a protein, may generate a set of observable traits called a phenotype. In the 
“central dogma” of molecular biology, gene expression is divided into two consecutive 
steps: the transcription of DNA to RNA and the translation of RNA to proteins (Figure 
1). This process is analogous to cooking a dish – that is, if we think of DNA as a 
cookbook, genes as individual recipes, and proteins as prepared dishes, then we can cook 
a recipe in two steps: first, by writing down the recipe onto a sheet of paper (transcription) 
and, second, by cooking the dish using the written instructions (translation). Our interest 
in gene expression stems from its implications for human health and the complex, highly 
regulated mechanisms underlying this vital process. Here, I explore how the first step of 
gene expression – transcription – is regulated by the enzyme RNA polymerase II.  
During gene 
transcription, a highly 
complex molecular machine 
copies the genetic 
information in DNA to a 
structurally similar molecule 
called RNA. In eukaryotes 
(organisms whose DNA is 
contained within a cell 
 
Figure 1. A depiction of the central dogma of molecular 
biology. Genetic information flows from DNA to RNA 
(transcription) and from RNA to protein (translation). 
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nucleus), RNA polymerase II (Pol II) forms the core of this molecular machine since it 
executes the polymerization of RNA in a manner that accurately reflects a particular 
genetic sequence of DNA. Pol II performs many functions critical to transcription; 
however, we typically regard transcription as a sequential process occurring in three main 
stages: initiation, elongation, and termination. During initiation, Pol II assembles with 
other proteins near the beginning of a gene. Afterwards, elongation occurs, during which 
Pol II reads a single strand of DNA, one base at a time, to create an RNA molecule from 
complementary nucleotides. Finally, during termination, the newly synthesized RNA is 
released, and Pol II disengages from the DNA (Figure 2). 
 
Figure 2. A simplified schematic of eukaryotic transcription and its three main stages: initiation, 
elongation, and termination. During initiation, Pol II binds to DNA with the help of transcription factors. 
Next, during elongation, Pol II travels along the DNA strand and synthesizes RNA. Finally, during 
termination, Pol II detaches from the DNA, and the newly synthesized RNA is made ready for 
translation.   
Throughout the different stages of transcription, Pol II switches between many 
different activities, allowing it to carry out numerous functions essential for regulating 
and accomplishing transcription. Regulatory proteins called transcription factors interact 
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with Pol II to help orchestrate transcription in general or to activate or repress the 
transcription of specific genes. While traversing the DNA, Pol II not only shifts its 
association with these different proteins but also changes its own conformation, speed 
and even direction. Due to the highly versatile nature of Pol II and the variety of 
transcription factors with which it interacts, the process of transcription is remarkably 
dynamic. The result of this complexity, however, is that many of the mechanisms by 
which transcription is regulated – even by Pol II – remain poorly understood.  
When visualizing the process of transcription, we typically imagine Pol II moving 
forward on the DNA, faithfully reading the sequences of DNA bases as it concurrently 
synthesizes RNA. During elongation, however, Pol II can also move backwards on the 
DNA, a phenomenon referred to as backtracking (Figure 3). When backtracking occurs, 
Pol II slides backwards on the DNA, displacing the growing end of the RNA from the 
active site (where new nucleotides are incorporated into the RNA) into a proposed 
“backtrack site.” Based on structural information provided by X-ray crystallography, the 
backtrack site comprises amino acid residues from the Pol II subunits Rpb1 and Rpb2 
that were observed to form stable interactions with the RNA1. These protein-RNA 
interactions cause Pol II to cease transcription, or arrest, while transcribing DNA. To 
escape arrest and resume elongation, Pol II must be reactivated by the transcription factor 
TFIIS.  
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Backtracking is a conserved property 
in homologous RNA polymerases from all 
domains of life. However, given that Pol II 
backtracking leads to transcription arrest, one 
might expect backtracking to be 
counterproductive to the function of Pol II. We 
can therefore deduce that backtracking is 
critical for some conserved function in RNA 
polymerases since this phenomenon would 
have otherwise been eliminated by evolution.  
Indeed, backtracking has been implicated in 
many processes essential for gene regulation, 
from modulating the speed of Pol II to 
ensuring proper termination and transcription 
fidelity (accuracy)2.  
To better understand the importance of 
individual residues in the Pol II backtrack site, 
previous lab members and I have created a 
DNA library of single mutations in yeast. Each 
single mutation hypothetically disrupts the 
interaction between RNA and a specific 
residue in the backtrack site, which allows us 
to characterize how these mutations affect the 
 
 
Figure 3. A simplified schematic of Pol II 
backtracking. Prior to backtracking, Pol II 
facilitates elongation by adding nucleotides to 
the growing RNA strand. When backtracking 
occurs, nascent RNA binds to the Pol II 
backtrack site, leading to transcription arrest. 
SII must then cleave RNA from the backtrack 
site to rescue Pol II and allow elongation to 
resume. 
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various functions of Pol II in vivo. My thesis, in particular, focuses on the residues that 
contribute to the Rpb1 region of the backtrack site and investigates their physiological 
role in transcription. To expand our DNA library of mutants, I have not only created a 
new mutation in Rpb1 but also engineered combinations of single mutations in the Rpb1 
region of the backtrack site. Our motivation for combining mutations comes from our 
desire to examine the physiological effects of severely disrupting the binding between 
RNA and the backtrack site – an aspect of our research that has hitherto been unexplored. 
We hypothesize that our new single mutation will impair RNA binding in a way that 
would generate a phenotype distinguishable from wild-type. Moreover, we hypothesize 
that our combined mutations will impair RNA binding even more and severely 
compromise the ability of Pol II to form a stable arrested complex. Such a mutant strain, 
we hypothesize, would not only produce a more deleterious phenotype but also enable us 
to better address what Pol II function might be compromised and its effects on the fitness 
of the cell.  
To investigate the behavior of Pol II, we use the fungus Saccharomyces cerevisiae 
(Baker’s yeast) as our model organism (Figure 4). As one of the most widely studied 
eukaryotic model organisms, yeast have contributed much to the pioneering research in 
genetics and molecular and cell biology. Several features make yeast an ideal model 
organism, including their accessibility, low cost of maintenance, rapid cell cycle, and ease 
of genetic manipulation. With a short doubling time of 1.5 to 2 hours, yeast can be grown 
rapidly in culture3. Cultured yeast can then be used for further manipulation, 
experimentation, and storage, making them highly versatile and sustainable in the lab. 
Through DNA transformation, a common technique in which exogenous DNA is 
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transferred into a cell, we can easily add or delete genes from the yeast genome. Yeast 
can be transformed in two ways, either by introducing circular DNA molecules (plasmids) 
into cells or by integrating DNA fragments into the yeast genome while eliminating  
undesired sequences (homologous recombination). 
Fortunately, the entire genome of S. cerevisiae has been determined, and its 
complete genomic sequence is stored in a public online domain called the Saccharomyces 
Genome Database (SGD). In the yeast genome, a subset of genes, including those 
encoding various Pol II subunits like Rpb1, are highly homologous to genes found in 
other eukaryotes like humans. In addition, an online archive called the Yeast Protein 
Database (YPD) compiles the complete set of proteins expressed by yeast and their 
corresponding structures, functions, and homologies to other proteins. The sequence 
homology between yeast polymerases and the polymerases of other eukaryotes is yet 
another reason for S. cerevisiae being our model organism of choice. Using such 
A.  
 
B. 
 
Figure 4. Yeast as the model organism in our study. (A) Scanning electron microscopy image 
of Saccharomyces cerevisiae, or Baker’s yeast. Budding yeast cells are noticeable, and visible 
scars on the surface of some cells are indicative of recent budding off of daughter cells after cell 
division. (Source: Thesis by Rasha Aref, University of Greifswald4). (B) Yeast colonies grown 
on agar plates. Colonies typically appear grey-white with a smooth surface. (Source: 
Department of Veterinary Disease Biology, University of Copenhagen5). 
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databases as SGD and YPD, we are not only able to compare wild-type and mutant 
sequences of yeast genes but also extrapolate information from the yeast genome and 
proteome to other eukaryotes like plants, animals, and humans.  
EXPERIMENTAL APPROACH 
The overarching goal of this project is to gain a broader understanding and appreciation 
of Pol II backtracking. In particular, we set out to investigate the physiological 
consequences of mutating the Rpb1 region of the Pol II backtrack site. When backtracking 
occurs, Rpb1 and Rpb2 residues bind to nascent RNA in a way that causes transcription 
to become arrested. Therefore, we can infer that mutating Rpb1 residues in the backtrack 
site would disrupt the protein-RNA interactions that arise from backtracking. In this 
project, we have created a new single mutation and engineered combinations of mutations 
in Rpb1 with the intent to extensively obliterate the protein-RNA backtracking 
interactions. Since backtracking is essential for transcription, interfering with the event 
would likely influence Pol II function and, by extension, transcription as a whole.  
Our experimental approach has two main phases, starting with the creation of 
mutant rpb1 yeast strains and culminating with the characterization of our mutants in 
vivo. The gene encoding Rpb1 is rather large, containing an open reading frame that is 
5,199 DNA base pairs (bp) long6. Due to the inconvenient size of the Rpb1 gene, we first 
used plasmids encoding a portion of Rpb1 that includes the backtrack site. These plasmids 
contain either wild-type sequences (used to generate single mutations) or mutant 
sequences (used to engineer combinations of mutations) that were generated by previous 
lab members. To introduce a mutation, we employed site-directed mutagenesis, a 
technique that enables us to make specific changes to the DNA sequence in a way that 
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alters the encoded protein sequence. In our case, we altered one or two bases on the DNA 
encoding the backtrack site to replace a particular Rpb1 amino acid residue with another. 
We induced these genetic changes such that the chemistry of the resulting residue is 
changed (see Figure A1 in the Appendix for a complete list of amino acids), allowing us 
to reduce or eliminate the interaction between the Pol II backtrack site and the RNA. Our 
final step in creating our mutants involves introducing the mutated sequence into yeast in 
the context of the entire rpb1 gene. 
 After mutagenesis, we added our mutant rpb1 sequences into yeast through 
homologous recombination. It is difficult to predict the effects of a mutation on an 
organism without scientific examination, so we proceeded to examine the effects of our 
mutations by conducting several in vivo tests. While most mutations tend to be neutral – 
that is, neither harmful nor beneficial – some mutations may generate a noticeable effect 
that either enhances or diminishes the fitness of an organism. The latter effect is more 
likely to occur, especially when considering the notion that an organism has evolved a set 
of genes best-suited for its environment. Under ideal laboratory conditions, yeast 
harboring mutations will often appear unaffected. However, under more stressful growth 
conditions, yeast mutants are more likely to show growth defects relative to wild-type. 
These differences in growth sensitivities can be extrapolated to changes in overall fitness 
or, for our purposes, to changes in Pol II function. In this project, we have characterized 
our mutants using in vivo assays that target a particular function of Pol II, such as its 
ability to proofread RNA and terminate transcription.  
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REVIEW OF LITERATURE 
Many biological processes essential to life on earth, such as cell division and 
differentiation, metabolism, growth, and homeostasis, are dependent on the regulation of 
gene expression. Each step in the flow of information from DNA to RNA to protein is 
intricately regulated by a vast network of proteins, and any perturbation to this high level 
of control poses a threat to the health and survival of the organism affected. Therefore, 
uncovering the mechanistic details of gene regulation and their potential implications to 
human health drives not only this project but also much of the research in genetics and 
molecular and cell biology.  
 As the first step of gene expression, transcription is a fundamental, highly 
regulated process that results in the production of RNA. In eukaryotic organisms, Pol II 
plays a central role in accomplishing transcription because it catalyzes the synthesis of 
messenger RNA (mRNA) using the information encoded in DNA. For a particular gene, 
the level of mRNA transcripts synthesized by Pol II typically corresponds to the amount 
of protein product. Gene expression, therefore, depends on the extent to which 
transcription is regulated. Since Pol II is the core enzyme involved in transcription, it 
must be tightly controlled so that transcription is carried our efficiently and faithfully. 
Transcriptional misregulation can lead to a broad range of diseases and syndromes in 
humans7, and given the central role of Pol II in eukaryotic transcription, many research 
groups continue to investigate the enzymology and biochemistry of Pol II. Such research 
provides key information crucial to this study, including the structure, function, and 
regulation of Pol II and the underlying mechanisms by which it transcribes DNA.  
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RNA POLYMERASE II STRUCTURE AND FUNCTION 
RNA polymerase II (Pol II) is composed of 12 subunits (Rpb1 to Rpb12) and has a 
combined mass greater than 550 kilodaltons (kDa)6. The amino acid sequences of all Pol 
II subunits in yeast have been determined6. Additionally, several X-ray crystal structures 
of Pol II have been elucidated, providing the structural basis for understanding 
transcription initiation and elongation and the various interactions between Pol II and its 
many transcription factors. Throughout the various stages of transcription and during 
instances when it binds other 
proteins, Pol II adopts a unique 
structural conformation. It is 
during these fortuitous moments 
that X-ray crystallography can 
provide meaningful structural 
information and emerging 
insights into the mechanism of 
transcription by Pol II.  
A high-resolution X-ray 
crystal structure of a 10-subunit 
yeast Pol II reveals that the cleft 
at center of Pol II has four mobile 
elements – namely, a “core,” 
“clamp,” “shelf,” and “jaw lobe” 
(Figure 5)6.  The core is the 
 
Figure 5. The 10-subunit yeast Pol II structure (from review 
by Steven Hahn8). (A) Diagram showing the top view of Pol 
II during elongation, containing DNA (blue and green), RNA 
(red), and the active site (magenta). (B) Space-filling model 
showing the side view of Pol II with the mobile elements and 
various subunits labeled by color.  
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largest of the four elements, containing Rpb1 and Rpb2 regions that form the active site 
and Rpb3, Rpb10, Rpb11, and Rpb12 subunits that are involved in Pol II assembly. 
During initiation, the clamp element, which comprises regions of Rpb1, Rpb2, and Rpb3, 
moves with a swinging motion over the cleft and active site, causing Pol II to adopt either 
an open or closed conformation. In the open conformation, the clamp swings open, 
allowing single-stranded DNA to insert into the cleft to reach the active site. The subunit 
Rpb7, which is not present in the aforementioned crystal structure, contributes to the 
closed conformation by locking the clamp in place. The other two elements, the shelf and 
jaw lobe, are made up of regions of Rpb1, Rpb5, and Rpb6 and Rpb1, Rpb2, and Rpb9, 
respectively. In contrast to the core and clamp, the shelf and jaw lobe elements rotate 
parallel to the cleft and generate relatively little movement. Such rotations, however, have 
been proposed to act as a “helical screw,” allowing DNA to advance toward the Pol II 
active site.  
For RNA synthesis to occur, substrate nucleotide triphosphates must enter the Pol 
II active site through a narrow, funnel-shaped channel9. In the active site, two magnesium 
ions and a “trigger loop” catalyze the incorporation of the nucleotide substrate to the 
growing end of the RNA. The trigger loop positions itself in the active site only when the 
correct substrate nucleotide (complementary to a particular DNA base) is present, 
sequestering the nucleotide in the active site so that it can be accurately incorporated to 
the nascent RNA10. Catalysis, as a result, is coupled to the selection of the correct 
nucleotide, allowing Pol II to synthesize RNA with high fidelity. After Pol II adds the 
correct nucleotide, it rapidly incorporates the next complementary nucleotide without 
having to disengage from the DNA strand. Altogether, Pol II and its consortium of 
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transcription factors accomplish transcription with remarkable accuracy, speed, and 
processivity.  
POL II BACKTRACKING: CAUSES, MECHANISM, AND FUNCTION 
During transcription, Pol II moves forward along the DNA and synthesizes mRNA. 
Transcription, however, is not a completely uniform process, as Pol II also backtracks, 
pauses, and arrests on the DNA. When extensive backtracking occurs, Pol II becomes 
arrested and transcription ceases. Various events have been linked to the onset of 
backtracking and arrest, such as the scarcity of nucleotides, the presence of nucleosomes 
and other obstacles on the DNA, torsional stress on the DNA due to supercoiling, DNA 
lesions, purine-rich segments of DNA, and nucleotide misincorporation11.  
 The proposed mechanisms by which Pol II backtracks depend on the extent of 
backtracking. Backtracking by one to two nucleotides typically occurs as a result of the 
erroneous nucleotide incorporation, causing transcription to pause12-13. Fortunately, Pol 
II can quickly resolve issues related to nucleotide misincorporation by virtue of its 
intrinsic nuclease activity that cleaves incorrect nucleotides from the growing end of the 
RNA. Such intrinsic activity requires the Pol II subunit Rpb914 and, oftentimes, the 
transcription factor SII (TFIIS)15. Thus, intrinsic cleavage is essential for Pol II to 
proofread its work and to ensure that transcription is accomplished with high fidelity.  
Pol II backtracking beyond two nucleotides is averted by favorable RNA base-
stacking interactions and by a “gating tyrosine” residue on Rpb21. However, if RNA base-
stacking interactions are weak, backtracking beyond two nucleotides may occur, allowing 
nascent RNA to bypass the gating tyrosine and intrude further into the backtrack site 
where it ultimately binds. Such extensive backtracking inhibits elongation and causes Pol   
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II to become arrested. Once arrested, 
Pol II cannot rely solely on its intrinsic 
cleavage activity to resume 
transcription; instead, it requires TFIIS 
to cleave the backtracked RNA. TFIIS 
rescues Pol II from arrest by displacing 
nascent RNA from backtrack site and 
inducing the cleavage of backtracked 
RNA, thereby generating a new RNA 
end in the Pol II active site and allowing 
transcription to continue (Figure 6).  
 Backtracking has been 
implicated in multiple processes 
essential for regulating and 
accomplishing gene transcription. 
Through backtracking, Pol II can 
regulate gene transcription by inducing 
regulatory pauses and arrests, 
modulating the rate of elongation, 
ensuring transcription fidelity, and 
contributing to cotranscriptional RNA 
folding and transcription termination2. 
Our study of Pol II, in particular, 
 
Figure 6. A more detailed schematic of Pol II pausing, 
backtracking, arrest, and reactivation (from Cheung 
and Cramer1). Pol II (grey) adds nucleotides to the end 
of the RNA strand (red) at the active cite (magenta). 
When extensive backtracking occurs, nascent RNA 
binds to the Pol II backtrack site (blue). TFIIS 
(orange) cleaves backtracked RNA to rescue Pol II 
from arrest.  
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investigates the importance of the backtrack site in regulating transcription fidelity, 
elongation speed, and termination in vivo.  
THE POL II BACKTRACK SITE 
Backtracking causes Pol II to switch between two different conformations – that is, from 
its “elongation complex” to an “arrested complex” – thereby causing transcription to 
cease. An X-ray crystal structure of the Pol II arrested complex has been solved, providing 
the structural basis for understanding the protein-RNA interactions that form during 
backtracking1. Structural comparisons between the elongation and arrested complexes of 
Pol II offer significant insights into Pol II’s backtracking activity relative to its primary 
function of catalyzing RNA synthesis.  
The Pol II backtrack site is composed of Rpb1 and Rpb2 regions that form stable 
interactions with backtracked RNA. However, the backtrack site is quite extensive and 
comprises five 
functional elements: the 
“bridge helix,” “trigger 
loop,” “fork loop,” 
“hybrid binding 
domain,” and “pore and 
funnel domain” (Figure 
7). The bridge helix, 
trigger loop, and pore 
and funnel domain are 
parts of Rpb1, whereas  
 
Figure 7. Structure of the Pol II arrested complex. Interactions between 
backtracked RNA (red) and the functional elements of the backtrack site 
are displayed: bridge helix (green), trigger loop (purple), fork loop 
(yellow), hybrid binding domain (teal), and funnel domain (lavender) 
(from Cheung and Cramer1).  
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the fork loop and hybrid binding domain are parts of Rpb2. When backtracking occurs, 
nascent RNA is extruded from the active site into the backtrack site, where it forms stable 
interactions with residues constituting all five functional elements.  
The structure of the aforementioned arrested complex reveals molecular 
interactions between the residues comprising the backtrack site and eight nucleotides of 
backtracked RNA (Figure 8a). The first backtracked RNA nucleotide (+2) interacts with 
residue T827 on the bridge helix and E529 on the fork loop and stacks between the +1 
nucleotide and residue Y769 (gating tyrosine) on the hybrid binding domain (Figure 8b). 
Backtracking beyond two nucleotides causes the backbone between nucleotides +2 and 
+3 to kink, and this kinked backbone contacts the R766 residue on the hybrid binding 
domain. The +3 nucleotide contacts the residues Q1078 and T1080 on the trigger loop. 
RNA that has backtracked beyond the +3 position interacts exclusively with the funnel 
domain of Rpb1. The backbone between nucleotides +3 and +4 contacts residue K752, 
 
Figure 8. Structure of the backtrack site in the Pol II arrested complex and the proposed interactions 
between Rpb1 and Rpb2 residues and backtracked RNA. (A) Side and front views of Pol II backtrack 
site residues contacting the backtracked RNA (color designations similar to Figure 7). (B) A simplified 
schematic of the interactions between backtrack site residues and backtracked RNA (from Cheung and 
Cramer1). 
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and the backbones between nucleotides +4 and +5 and between +5 and +6 both contact 
residue S754. The base of nucleotide +6 inserts into a funnel pocket containing residues 
R726 and I756. The backbone between nucleotides +6 and +7 kinks again, causing 
nucleotide +7 to contact residue R731 and to base stack between residue F755 and 
nucleotides +8 and +9. In this project, we focus on three Rpb1 residues comprising the 
backtrack site: R726, T827, and K752. We mutated the DNA encoding these residues in 
order to disrupt their interactions with RNA and to assess their effects on Pol II function 
and cell fitness.  
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MATERIALS AND METHODS 
Growth medias 
Escherichia coli was cultured in Luria-Bertani (LB) broth containing 1% tryptone, 
0.5% yeast extract, and 1% NaCl at pH 7.5. Ampicillin was added to a final concentration 
of 100 μg/ml in LB broth containing 1.5% agar to select for resistant bacteria. 
Saccharomyces cerevisiae was cultured in synthetic complete (SC) dropout media broth 
containing 0.67% bacto-yeast nitrogen base and 2% glucose and lacking amino acids used 
for selection16. Media for the blue/white screen contained 2% galactose instead of 
glucose.  Transformations, serial dilutions, and yeast grown for the colony lift assay were 
plated on media made from SC dropout broth containing 2% bacto-agar.  
rpb1 mutagenesis 
In this project, four rpb1 mutants were generated: one single mutant (K752T), two 
double mutants (R726S + K752T and K752T + T827A), and a triple mutant (R726S + 
K752T + T827A)*. Two other rpb1 single mutants (R726S and T827A) were obtained by 
previous lab members (Table 1). We also engineered two restriction sites into the mutant 
containing the R726S mutation. The DNA sequence of the Rpb1 backtrack site is 
provided in the Appendix (Figure A2). A complete list of the yeast strains, plasmids, and 
primers used in this study are summarized in Table 2.  
 
 
 
                                                 
* The standard mutation nomenclature for amino acid changes are described in three parts, in the 
following order: a one-letter abbreviation for the original amino acid, a number denoting the position of 
the amino acid in the peptide sequence, and a one-letter abbreviation for the new amino acid.  
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TABLE 1.  RPB1 MUTATIONS IN THIS STUDY 
Mutation Method of Mutagenesis  Created by 
R726S# Random, obtained in screen Yerim Lee17 
K752T Site-directed  Joshua Mostales 
T827A Site-directed  Mandi Severson18 
R726S + K752T Site-directed^  Joshua Mostales 
K752T + T827A Site-directed^ Joshua Mostales 
R726S + K752T + T827A Site-directed^ Joshua Mostales 
#Sequence containing the R726S mutation was engineered in this study to have two 
restriction sites flanking the mutation.  
^Site-directed mutagenesis was performed using plasmids already containing rpb1 
mutations.  
 
Creation of single mutation K752T and introduction of restriction sites near 
mutation R726S. To produce the single mutation K752T, site-directed mutagenesis of 
the DNA sequence encoding the Rpb1 backtrack site was performed by PCR 
amplification of the region in a TOPO vector coding for wild-type Rpb1 (pDH442) using 
primers DHO473 and DHO436. The mutagenic forward primer (DHO473) introduced 
the mutation K752T into the amplified sequence (Figure 9a). Mutagenic PCR fragments 
and the TOPO vector were purified, digested with the restriction endonucleases BamHI 
and XbaI, and ligated together prior to transformation into E. coli (Figure 9b). Colonies 
resulting from the transformation were isolated, and bacterial minipreps were performed 
to extract the DNA from the bacteria. To confirm the presence of the mutation in the 
recombinant plasmid, the DNA was sent for sequencing using the primer DHO436 which 
anneals close to the mutated sequence.  
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Figure 9. Creation of single mutation K752T and introduction of restriction sites near mutation R726S. 
(A) Schematic of the RPB1 region encoding the backtrack site. Codons for residues of interest (R726, 
K752, T827) are labeled. Half arrows denote the annealing location of forward (f) and reverse (r) primers 
used in this study and their mutagenic effects (if any) on the wild-type sequence. Restriction sites for 
EagI and XbaI occur naturally in this sequence. (B) Schematic outlining the steps taken to generate 
mutation K752T. (C) Schematic outlining steps taken to introduce BamHI and DraIII restriction sites on 
the sequence containing mutation R726S.  
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To introduce the restriction sites for BamHI and DraIII near the region encoding 
the mutation R726S, site-directed mutagenesis was performed by PCR amplification of 
the region in the pRP114 plasmid encoding rpb1 R726S (pDH191) using primers 
DHO471 and DHO470 (Figure 9c). The mutagenic forward primer (DHO471) introduced 
the DraIII site, and the mutagenic reverse primer (DHO470) introduced the BamHI 
restriction site. Mutagenic PCR fragments containing mutation R726S and the TOPO 
vector pDH442 were purified, digested with the restriction endonucleases BamHI and 
DraIII, and ligated together prior to transformation into E. coli. Colonies resulting from 
the transformation were isolated, and bacterial minipreps were performed to extract the 
DNA from the bacteria. To confirm the presence of the mutation and restriction sites in 
the recombinant plasmid, the DNA was sent for sequencing using the primer DHO436 
which anneals close to the mutated sequence.  
Creation of double mutations R726S + K752T and K752T + T827A. To produce 
the double mutation R726S + K752T, PCR amplification of the TOPO vector encoding 
rpb1 K752T (pDH445) was performed using primers DHO473 and DHO436 (Figure 
10a). PCR fragments containing mutation K752T and the TOPO vector containing 
mutation R726S (pDH446) were purified, digested with the restriction endonucleases 
BamHI and XbaI, and ligated together prior to transformation into E. coli. Colonies 
resulting from the transformation were isolated, and bacterial minipreps were performed 
to extract the DNA from the bacteria. To confirm the presence of the two mutations in 
the recombinant plasmid, the DNA was sent for sequencing using the primer DHO436 
which anneals close to the mutated sequence.  
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Figure 10. Creation of double mutations R726S + K752T and K752T + T827A. (A) Schematic outlining 
the steps taken to generate mutations R726S + K752T. (B) Schematic outlining the steps taken to 
generate mutations K752T + T827A. A more detailed schematic of the RPB1 region encoding the 
backtrack site (shown in light blue) is provided in Figure 9a. 
 
To generate the double mutation K752T + T827A, site-directed mutagenesis was 
performed by PCR amplification of the pRP114 plasmid encoding rpb1 T827A (pDH422) 
using primers DHO473 and DHO436. The mutagenic forward primer (DHO473) 
introduced the mutation K752T and a BamHI restriction site into the amplified sequence 
(Figure 10b). Mutagenic PCR fragments containing mutations K752T and T827A and the 
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TOPO vector pDH442 were purified, digested with the restriction endonucleases BamHI 
and XbaI, and ligated together prior to transformation into E. coli. Colonies resulting from 
the transformation were isolated, and bacterial minipreps were performed to extract the 
DNA from the bacteria. To confirm the presence of the two mutations in the recombinant 
plasmid, the DNA was sent for sequencing using the primer DHO436 which anneals close 
to the mutated sequence.   
Creation of triple mutation R726S + K752T + T827A. PCR amplification of the 
TOPO vector containing the mutation R726S and the engineered BamHI and DraIII 
restriction sites (pDH446) was performed using primers DHO470 and DHO470 (Figure 
11). The resulting PCR fragment containing R726S and the TOPO vector containing the 
mutations K752T and T827A (pDH447) were purified, digested with the restriction 
endonucleases DraIII and BamHI, and ligated together prior to transformation into E. 
coli. Colonies resulting from the transformation were isolated, and bacterial minipreps 
were performed to extract the DNA from the bacteria. To confirm the presence of the 
three mutations in the recombinant plasmid, the DNA was sent for sequencing using the 
primer DHO436 that anneals close to the mutated sequence.  
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Figure 11. Creation of triple mutation R726S + K752T + T827A.  The schematic outlines the steps taken 
to generate triple mutation. A more detailed schematic of the RPB1 region encoding the backtrack site 
(shown in light blue) is provided in Figure 9a.  
 
Creation of mutant rpb1 yeast strains. To generate mutant yeast strains, the yeast 
plasmid pRP114 containing the entire RPB1 gene was used for homologous 
recombination (pDH443) (Figure 12). PCR was performed on the appropriate mutant 
TOPO vector using primers DHO435 and DHO436 to generate DNA fragments 
containing the mutation(s) of interest. For homologous recombination to occur, the 
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pRP114 plasmid was digested with the restriction endonucleases XbaI and EagI, and the 
resulting cut plasmid was combined with the PCR product through transformation with 
competent yeast cells (DHY464), allowing the wild-type sequence encoding the Rpb1 
backtrack site to be replaced with the mutant sequence contained in the PCR product.  
Since pRP114 contains the gene LEU2, transformations were done on leucine-selective 
media (SC-Leu) to select for cells containing the intact pRP114 that resulted from 
recombination. Transformant colonies were streaked onto SC-Leu media containing 5-
fluoroorotic acid (5-FOA) to cure cells of the pRP112 plasmid that contains wild-type 
RPB1. Plasmids were subsequently extracted from yeast cells, transformed into E. coli, 
isolated from resulting bacterial colonies, and sent for sequencing to confirm the presence 
of rpb1 mutations (using primer DHO436).  Once the sequences were confirmed to have 
the correct mutation(s), wild-type (pDH443) and mutant (pDH450, pDH451, pDH452, 
pDH453) pRP114 plasmids were transformed into yeast (DHY678). Cells were plated 
onto SC-Leu to allow for the selection of colonies that have effectively incorporated the 
pRP114 plasmid. Transformant colonies were streaked onto SC-Leu media containing 5-
FOA to cure cells of the pRP112 plasmid containing wild-type RPB1.  
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Figure 12. Yeast homologous recombination. rpb1 mutants were created by transformation of yeast 
pRP114 vector (digested with XbaI and EagI restriction endonucleases) and mutagenic rpb1 PCR 
fragments. 
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Characterization of rpb1 mutations.  
Temperature sensitivity. The overall fitness of mutant rpb1 strains was assayed 
using a spot test analysis. Mutant rpb1 strains cured of pRP112 were grown to log-phase. 
Cells were diluted to an optical density (OD) of 0.6 at a wavelength of 600 nm (OD600 = 
0.6), and then fivefold serial dilutions of log-phase cells were spotted onto YEPD media 
using a 48-well frogger. Cells were incubated at 18°C, 30°C, and 38°C and scored relative 
to wild-type after 3-7 days of incubation.  
Drug sensitivity. Sensitivity to the drugs canavanine and mycophenolic acid 
(MPA) were tested to gain an initial assessment of Pol II fidelity and elongation speed, 
respectively. Mutant rpb1 strains cured of pRP112 were grown to log-phase. Cells were 
diluted to OD600 = 0.6, and fivefold serial dilutions of log-phase cells were spotted using 
a 48-well frogger onto either leucine- and arginine-selective media (SC-Leu-Arg) 
containing 500 μg/mL canavanine or Sc-Leu media containing 50 μg/mL MPA. Strains 
spotted on control plates without drugs (SC-Leu) were assessed after 2-3 days of 
incubation at 30°C. Strains were scored relative to wild-type after 6 days of incubation at 
30°C.  
Blue/white screen. Termination efficiency was assayed using a colony lift 
colorimetric assay for β-galactosidase. Mutant rpb1 alleles on pRP114 were introduced 
into yeast strains containing the pL101Btrp reporter plasmid (DHY709) through yeast 
transformation. Cells were plated on leucine- and tryptophan-selective media (SC-Leu-
Trp) to select for colonies that have effectively incorporated the pRP114 and retained the 
pL101Btrp plasmids. Transformant colonies were streaked onto SC-Leu-Trp media 
containing 5-FOA to cure cells of the pRP112 plasmid containing wild-type RPB1. Cured 
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cells were cultured and aliquoted onto tryptophan-selective (-Trp) galactose media to 
induce the expression of the lacZ. Colonies were transferred onto filter paper, briefly 
submerged in liquid nitrogen to induce cell lysis, and exposed to X-gal to indicate the 
expression of lacZ. Up to 24 hours after X-gal exposure, mutant colonies were evaluated 
for termination deficiencies based on their color intensities relative to wild-type colonies.  
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RESULTS AND DISCUSSION 
RNA polymerase II is the core enzyme that catalyzes gene transcription in eukaryotic 
cells. During transcription, Pol II moves forward along the DNA and synthesizes 
messenger RNA. Under certain circumstances not yet fully understood, Pol II backtracks 
on the DNA, causing transcription to arrest. When backtracking occurs, nascent RNA is 
extruded from the active site into a backtrack site containing Rpb1 and Rpb2 residues that 
are proposed to form stable interactions with the RNA. TFIIS must cleave the RNA bound 
to the backtrack site in order for transcription to resume. To better understand the 
physiological relevance of Pol II backtracking, we have created mutations in the Rpb1 
region of the backtrack site and characterized yeast strains harboring these mutations in 
vivo. Since these mutations impair the proposed interactions between nascent RNA and 
the backtrack site, we assessed the effect of these mutations on cell viability. We also 
examined the growth phenotypes of mutant strains under conditions that place stress on 
cell fitness and on various Pol II functions, such as elongation, start site recognition, and 
proofreading, and we also assessed termination by Pol II using a lacZ reporter assay.  
CREATION OF MUTANTS 
In this work, we created four novel yeast strains containing mutations in rpb1: one single 
mutation (K752T), two double mutations (R726S + K752T and K752T + T827A), and 
one triple mutation (R726S + K752T + T827A). Two single rpb1 mutants (R726S and 
T827A) were obtained by previous lab members (Table 1). Our residues of interest 
constitute the Rpb1 region of the Pol II backtrack site (Figure 13). In wild-type Rpb1, the 
arginine residue at position 726 contributes to the “funnel pocket” that contacts the fifth  
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backtracked RNA nucleotide. Since arginine is a 
basic side chain (which makes it positively charged 
under physiological conditions), our R726S 
mutation eliminates this positive charge and 
replaces arginine with a polar, partially negative 
serine side chain. Our second residue of interest, the 
lysine at position 752, is proposed to interact with 
the RNA backbone between the second and third 
backtracked nucleotide. Given that lysine is 
positively charged and the RNA backbone is a 
negatively charged, the interaction between K752 
and the RNA backbone is believed to be 
electrostatic in nature. Our K752T mutation 
substitutes the lysine residue at this position with a threonine residue, which has a polar 
side chain that would hypothetically create unfavorable interactions with the RNA 
backbone and thereby impair the binding of backtracked RNA. Finally, our third residue 
of interest, the threonine at position 827, is proposed to interact with the first backtracked 
RNA by virtue of its polar side chain. Our T827A mutation alters the threonine at this 
position to an alanine, which abolishes any polar interactions that might arise between 
this residue and backtracked RNA. In addition to our single rpb1 mutants, we also 
engineered combinations of mutations with the intent to significantly impair RNA 
binding with the backtrack site. Altogether, these rpb1 mutations alter the chemistry of 
 
Figure 13. Structure of the backtrack 
site in the Pol II arrested complex 
containing Rpb1 (blue), Rpb2 (pink) 
and backtracked RNA (red). Our three 
residues of interest – R726, K752, and 
T827 – are labeled. Figure generated 
using PyMol software (adapted from 
Cheung and Cramer1, RCSB: 3PO2).  
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the backtrack site in order to hypothetically disrupt the protein-RNA interactions that are 
necessary to form the Pol II arrested complex. 
 To create our mutant yeast strains, we first introduced the engineered mutations 
into the pRP114 plasmid through yeast homologous recombination, confirmed the 
presence of rpb1 mutations on the pRP114 plasmid, and transformed these plasmids into 
yeast. We subsequently cured cells of the pRP112 plasmid containing wild-type RPB1 by 
streaking transformants onto media containing 5-FOA. Interestingly, after plating our 
various strains onto 5-FOA-containing media, we obtained many colonies for our single 
mutants and no colonies for 
our double and triple mutants 
(Figure 14). This result 
strongly suggests that the 
double and triple mutations 
prevented Pol II from 
supporting viability in the 
absence of wild-type Pol II. 
The lethality of our double 
and triple mutants may be 
due to the disruption of the 
interactions between RNA and the Pol II backtrack site.  
Altogether, these results show that cells can survive if they contain both wild-type 
and mutant variants of Pol II (since we obtained transformants prior to streaking on 5-
 
Figure 14. Various yeast strains streaked onto media containing 
5-FOA to cure cells of pRP112 containing wild-type RPB1. Wild-
type and single mutant strains (T827A not shown) produced 
colonies. Our double and triple mutant strains  did not produce any 
colonies. DHY678 is the negative control strain lacking pRP112.  
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FOA), but cells cannot survive with Pol II variants alone, in the absence of wild-type Pol 
II (since we did not obtain colonies for our double and triple mutants on 5-FOA).  
Previously, we performed the same steps to create strains of our double and triple 
mutants. We transferred transformant colonies onto 5-FOA to cure cells of pRP112, and 
intriguingly, we obtained many colonies for our single mutants and a few colonies for our 
double and triple mutants (data not shown). We transferred our double- and triple-mutant 
colonies from our 5-FOA plates onto SC-Leu plates to give cells harboring pRP114 the 
opportunity to grow even more. After obtaining colonies on SC-Leu plates, we streaked 
these colonies onto 5-FOA and, similar to our initial 5-FOA plates, obtained little or no 
colonies for our double and triple mutants (data not shown).  
The few double- and triple-mutant colonies that were obtained from our initial 5-
FOA plates were characterized in vivo using a spot test analysis at 30°C. We observed 
growth phenotypes similar to that of the wild-type RPB1 strain (data not shown), 
suggesting that our double and triple mutants that grew on 5-FOA may have harbored 
undesired mutations that allowed them to appear similar to wild-type. There are several 
possible explanations for these observed phenotypes, and each explanation may be 
attributable to an overall increase in mutation rate caused by combining rpb1 mutations. 
First, our double and triple mutants may have harbored mutations in the URA3 gene, 
which would prevent 5-FOA selection against cells containing wild-type RPB1 on 
pRP112. As a result, colonies harboring ura3 mutations would still express wild-type 
RPB1, grow on media containing 5-FOA, and exhibit a wild-type growth phenotype on a 
spot test. Second, the rpb1 gene in our double and triple mutants may have reverted back 
to wild-type RPB1 (by homologous recombination between wild-type RPB1 on pRP112 
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and mutant rpb1 on pRP114). In this scenario, cells could still be cured of RPB1 on the 
pRP112 plasmid, but they would still contain and express wild-type RPB1 on the pRP114 
plasmid. Third, our double and triple mutants may have harbored mutations on genes 
other than URA3 or RPB1 that might suppress the mutant phenotype. Such a mutation, 
although highly unlikely and difficult to ascertain, could also explain the observed 
phenotypes of our double and triple mutants.   
Overall, these observed discrepancies between our single mutants and our double 
and triple mutants suggest that combining backtrack site mutations, which severely 
disrupt the protein-RNA interactions that arise from backtracking, might increase the 
overall frequency of mutations. One possible explanation for the observed lethality of our 
double and triple mutants is that the backtrack site is important for preventing more 
extensive backtracking from occurring. That is, the residues constituting the backtrack 
site might inhibit further backtracking by “catching” backtracked RNA and preventing 
Pol II from sliding backwards. Thus, if the backtrack site is significantly impaired, further 
backtracking can occur by many nucleotides, resulting in genomic instability and 
increased mutation frequency2,19. This would explain the growth of only a few colonies 
on 5-FOA, as these colonies might have incurred mutations that confer 5-FOA resistance 
or allow cells to exhibit a wild-type growth phenotype.  
IN VIVO CHARACTERIZATION OF MUTANTS 
Temperature. After establishing that our single mutants were viable and our double and 
triple mutants were inviable, we investigated the effects of our rpb1 single mutations on 
the fitness of the cell. Growth comparisons at stressful temperatures can reveal 
differences in cell fitness between wild-type and mutant strains. In our study, we 
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introduced mutations in the Rpb1 region of the backtrack site, which hypothetically 
compromises the normal backtracking activity of Pol II, and examined the relative fitness 
our mutant strains at three different temperatures (18 °C, 30 °C, and 38°C) using a series 
of spot tests (Figure 15). We scored mutant growth phenotypes relative to wild-type using 
a scoring key outlined in Table 3. Yeast grown at temperatures near 30 °C grow optimally, 
while yeast grown at 18 °C and 38 °C are under cold and heat stress, respectively. At 
optimum temperatures (30 °C), our R726S and K752T mutants grew normally, whereas 
our T827A mutant grew significantly worse than the other strains (<<). Under heat stress 
(38 °C), our R726S and K752T mutants also grew similarly to wild-type, while our 
T827A mutant exhibited significantly less growth (<<). Growth sensitivities at 18 °C 
were more pronounced, with our K752T mutant growing much worse than wild-type (<<) 
and our T827A mutant exhibiting very little growth (<<<) even after 8 days. Only the 
R726S mutant grew similarly to wild-type at 18 °C. The data for our temperature 
sensitivity assay are summarized in Table 3.  
 
Figure 15. Cell fitness phenotypes of our rbp1 single mutant strains at 30 °C (after 3 days), 38 °C (after 
3-4 days), and 18 °C (after 7-8 days).  
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TABLE 3. TEMPERATURE SENSITIVITY PHENOTYPES OF RPB1 MUTANTS 
Mutation 30 °C 38 °C 18 °C 
R726S WT WT WT 
K752T WT WT << 
T827A << << <<< 
Scoring key (relative to wild-type): < slightly less growth, << significantly 
less growth, <<< extreme growth defect 
 The results of our temperature sensitivity assay suggest that under ideal growth 
conditions, the R726S and K752T mutations each do not reduce the overall fitness of the 
cell. Interestingly, even under thermal stress at 18 °C and 38 °C, the R726S mutation does 
not confer any phenotype that compromises cell fitness. Furthermore, the K752T 
mutation is detrimental to the cell only under cold stress, whereas the T827A mutation 
reduces cell fitness even at normal temperatures. Thus, the novel mutation created in this 
project, K752T, appears intermediate between R726S and T827A in terms of its effects 
on cell fitness.  
Canavanine. To examine the effects of our rpb1 mutations on transcription 
fidelity, we screened our mutants for sensitivity to canavanine. Canavanine is a toxic 
chemical that is structurally analogous to the amino acid arginine. Arginine and 
canavanine are both imported into yeast cells by an arginine permease encoded by the 
CAN1 locus. The strains used in this study contain a can1-100 gene containing a 
premature translation stop codon. This mutant can1-100 gene prevents the expression of 
the arginine permease, thereby resulting in canavanine resistance. However, Pol II can 
potentially introduce transcriptional errors that allow the expression of the arginine 
permease encoded in the can1-100 allele, causing canavanine import into the cell and 
possible lethality14. Errors in transcription, or reduced transcription fidelity, can be 
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attributed to various processes, including issues related to Pol II’s intrinsic nuclease 
activity, backtracking and elongation speed.  
 Our results demonstrate that all rpb1 mutants exhibit some level of canavanine 
sensitivity (Figure 16). The K752T and T827A mutants were lethal when grown with 
with canavanine (no growth after 7 days), while the R726S mutant exhibited considerable 
sensitivity to canavanine (<<). The results of our canavanine assay (summarized in Table 
4) suggest that the Rpb1 backtrack site residues K752 and T827 are essential for the 
ability of Pol II to proofread RNA and ensure transcription fidelity. Unlike the K752T 
and T827A mutants, however, the R726S mutant does not display a lethal phenotype 
when grown with canavanine. Nonetheless, its sensitivity to canavanine suggests that the 
R726 residue is somewhat important for transcription fidelity.  
 Our control plate (SC-Leu) shows that there was an issue with plating the serial 
dilutions, since some mutants did not show a serial decrease in cell concentration (e.g., 
K752T). Furthermore, our wild-type strain grew the worst on the control plate, another 
indication that errors were made in plating or diluting the cells. Nonetheless, the results 
demonstrate that there were defects in transcription fidelity, since the K752T and T827A 
mutants did not exhibit any growth with canavanine. To draw more definitive conclusions 
about the effects of these mutations on transcription fidelity in vivo, this assay must be 
replicated without errors in plating or making serial dilutions.  
Mycophenolic acid. To investigate the effects of our rpb1 mutations on 
elongation speed and start site recognition, we screened our mutants for sensitivity to 
mycophenolic acid (MPA). MPA is a competitive inhibitor of the major form of IMP 
dehydrogenase (IMPDH), an enzyme involved in guanosine triphosphate (GTP) 
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biosynthesis. GTP is a nucleotide needed for RNA synthesis; therefore, exposure to MPA 
will result in decreased intracellular levels of GTP and create issues related to 
transcription elongation. The IMD2 gene, which encodes IMPDH, has two start sites for 
transcription: an upstream start site used when GTP levels are high and a downstream 
start site used when GTP levels are low20. Use of the upstream start site results in 
premature termination of transcription and no production of the enzyme, while use of the 
downstream start site results in the expression of IMPDH. Additionally, use of the 
upstream and downstream start sites have been associated with a fast and slow elongation 
speeds, respectively. Wild-type Pol II can shift between both start sites depending on the 
intracellular abundance of GTP; however, some Pol II mutants have been shown to have 
problems shifting between the two sites or to prefer one site over the other20.  
 We observed that all rpb1 single mutants display no sensitivity to MPA (Figure 
16). The results of the MPA assay (summarized in Table 4) indicate that the Rpb1 
backtrack site residues R726, K752, and T827 likely do not increase the elongation speed 
of Pol II and/or influence its ability to recognize appropriate start sites for transcription. 
Previous unpublished data from the lab also indicates that the R726S variant has a 
preference for downstream start sites, which is consistent with the lack of MPA sensitivity 
shown in this study. Altogether, our results suggest that the Pol II variants under study 
can react to GTP depletion quite well by recognizing the downstream start site, thereby 
increasing the expression of IMP dehydrogenase. Our results also suggest that the Pol II 
variants might elongate similarly or more slowly than wild-type, since the use of 
downstream start sites is correlated with slow elongation speeds. However, we would 
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need to explicitly demonstrate that these Pol II variants exhibit slower elongation speeds 
and recognize the downstream start site to be certain of these conclusions.  
 
Figure 16. Drug sensitivity phenotypes of our rbp1 single mutant strains (after 7 days). The strain ∆SII 
is a control strain lacking the transcription factor TFIIS.  
 
TABLE 4. DRUG SENSITIVITY PHENOTYPES OF RPB1 MUTANTS 
Mutation Canavanine MPA 
R726S << WT 
K752T lethal WT 
T827A lethal WT 
Scoring key (relative to wild-type): < slightly less growth,  
<< significantly less growth, <<< extreme growth defect 
Because of issues related to diluting or plating the cells (as revealed by the growth 
phenotypes on the control plate), it is difficult to ascertain that our mutants were not 
MPA-sensitive. Given that the wild-type strain grew worst on the control plate, it might 
be that the mutants are less sensitive to MPA than wild-type. In particular, the T827A 
mutant might be the least MPA-sensitive, since it had the worst growth phenotype among 
all the single mutants and exhibited significant growth defects under optimal conditions 
(Figure 15), yet it grew similarly to wild-type when grown with MPA. Therefore, this 
assay must be repeated without errors in plating or making serial dilutions in order to 
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draw more definitive conclusions about the effects of these mutations on elongation speed 
and start site recognition in vivo.  
 Blue/white screen. Using a lacZ reporter assay, we screened our rpb1 mutants 
for defects in transcription termination. We introduced our rpb1 mutants to strains 
containing the β-galactosidase reporter plasmid pL101Btrp. This plasmid contains the 
lacZ gene from E. coli, a yeast GAL10 promoter, and a polyadenylation-dependent 
termination signal from the ADH2 gene between the GAL10 promoter and lacZ coding 
sequence (Figure 17). The ADH2 terminator was placed within the intron of the gene 
RP51, which encodes a yeast ribosomal protein. Galactose (in the absence of glucose) 
induces transcription from the GAL10 promoter, and Pol II will either terminate 
transcription due to the ADH2 terminator or fail to terminate, resulting in the expression 
of the downstream lacZ reporter gene. The protein encoded by lacZ is β-galactosidase, an 
enzyme that turns the chemical X-gal into a blue-colored product. In this assay, the 
intensity of the blue color is proportional to the extent of terminator read-through – that 
is, any color darker than wild-
type indicates defects related to 
transcription termination, 
whereas any color lighter than 
wild-type denotes improved 
termination efficiency.  
We observed a white phenotype for all our rpb1 single mutants (Figure 18). These 
results suggest that mutating the residues R726, K752, and T827 causes increased  
 
Figure 17. Schematic of the lacZ reporter construct used in 
our blue/white assay.  
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termination efficiency 
since the Pol II variants do 
not read through the ADH2 
terminator. Consistent with 
our results from the MPA 
assay, which suggest that 
our Pol II variants are slow 
elongating polymerases, 
we surmise that our 
mutants in the lacZ assay 
appear white because their 
polymerases elongate more 
slowly than wild-type. Slower polymerases, we hypothesize, recognize the ADH2 
termination sequence more accurately, preventing expression of the downstream lacZ 
gene. The data for our blue/white screen is summarized in Table 5. 
TABLE 5.  BLUE/WHITE SCREEN OF RPB1 MUTANTS 
Mutation Positions on Figure 18  Color 
WT #1 A1-A5 Green 
WT #2 E1-E5 Green 
R726S #1 B1-B5 White 
R726S #2 F1-F5 White 
K752T #1 C1-C5 White 
K752T #2 A6, B6, C6, D7, E7 White 
T827A #1 D1-D5 White 
T827A #2 B7, C7, D6, E6, F6 White 
 
Figure 18. Blue/white phenotypes of our rbp1 single mutant strains. 
Blue colonies (not shown) are indicative of ADH2 termination read-
through and lacZ expression, whereas white colonies are indicative 
of efficient termination. Wild-type colonies appear green due to a low 
frequency of read-through. The position of each mutant in the figure 
is specified in Table 5.  
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Altogether, although our data are rather preliminary, they indicate that residues 
constituting the Rpb1 region of the backtrack site have an important role in ensuring cell 
viability and regulating various aspects of transcription, including transcription fidelity, 
elongation speed, and termination efficiency. Our single mutants do not exhibit 
drastically different phenotypes, which is consistent with the notion that they share the 
same proposed role of contacting backtracked RNA and contributing to the formation of 
the arrested Pol II complex. By contrast, the double and triple mutants, which 
significantly impair the binding of RNA to the backtrack site, were inviable, suggesting 
that backtrack site might have an essential role in ensuring cell viability. It might be 
possible that the backtrack site is required to prevent Pol II from backtracking even 
further, since the backtrack site supposedly forms stable interactions with the backtracked 
RNA. In such a scenario, if the backtrack site is significantly impaired, further 
backtracking can occur by many nucleotides, resulting in genomic instability and 
increased mutation frequency2,19. This model, while not yet established in the field of 
backtracking research, provides a potential explanation for the observed lethality of our 
double and triple mutants.  
In contrast to our double and triple mutants, our single mutants were viable, but 
two of them (K752T and T827A) exhibited some diminished cell fitness relative to wild-
type. With our data, we can construe how each single mutation affects the ability of Pol 
II to accomplish transcription efficiently, particularly in the context of its backtracking 
activity. One possibility for the variation in cell viability across all three mutants is their 
relative position to one other (Figure 8b) and their likelihood of contacting backtracked 
RNA. The T827A mutation contacts the first backtracked RNA nucleotide (nearest the 
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active site), the position where misincorporated nucleotides are intrinsically cleaved by 
Pol II. The frequency of backtracking by one nucleotide, therefore, may be higher than 
more extensive backtracking, especially when taking into consideration the importance 
of Pol II proofreading and high-fidelity transcription for the survival of the cell2,14,15,21. 
By contrast, the mutations K752T and R726S are deeper in the backtrack site, the former 
contacting the backbone between the second and third backtracked nucleotides and the 
latter contacting the fifth backtracked nucleotide. One hypothesis for the role of the 
backtrack site is to prevent further backtracking from occurring and causing genomic 
instability2,19. With this notion, we can infer that residues deeper in the backtrack site may 
not encounter backtracked RNA as frequently because residues closer to the active site 
will “catch” the RNA before it backtracks even further.  This idea is in line with the 
observed mutant phenotypes since the R726S mutation is furthest from the active site and 
exhibits the highest cell fitness amongst all the single rpb1 mutants in our study.  
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PERSPECTIVES AND FUTURE DIRECTIONS 
 The results of our study offer emerging insights into the importance of the Pol II 
backtrack site and the physiological role of backtracking. Backtracking has been 
implicated in various processes essential for gene regulation, such as modulating the rate 
of elongation, ensuring transcription fidelity, and promoting efficient termination2. While 
our present study characterizes backtracking in these different contexts, further 
experiments must be conducted to further support or refute our results and to elucidate 
the various other roles of backtracking. In particular, the experiments performed in this 
study should be replicated to ensure consistency in the observed phenotypes. We can also 
assess transcription fidelity, elongation speed, start site usage recognition directly by 
employing various in vitro assays that assess mutation rates, elongation rates, and start 
site usage. We can also use other assays that target other Pol II functions, such its intrinsic 
nuclease activity and processivity, to gain a better understanding of the functional 
importance of the backtrack site.  
Although we achieved our goal of combining mutations in the Rpb1 region of the 
backtrack site, we were unable to characterize their effects on transcription fidelity, 
elongation speed, and termination efficiency in vivo. Given the lethality of our double 
and triple mutants on 5-FOA, we can also explore several reasons for their lack of growth. 
Rather than eliminating the wild-type RPB1 gene (on pRP112) in strains harboring rpb1 
double and triple mutations (on pRP114), we might be able to assess how having both 
wild-type and mutant Pol II’s influences cell viability and transcription relative to strains 
only containing wild-type RPB1. For example, without eliminating the wild-type RPB1 
gene, we can determine whether our double and triple mutants harbored any mutations 
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that would cause them to exhibit a wild-type growth phenotype by sequencing the URA3 
and RPB1 genes in these strains and identifying any mutations that would confer 
resistance to 5-FOA or revert the strain to wild-type, respectively. In strains containing 
both wild-type and mutant polymerases, we can also examine mutation rates to 
investigate the notion that eliminating the interactions between backtracked RNA and the 
backtrack site leads to genomic instability. 
It would be interesting to introduce our rpb1 mutations into yeast strains 
containing TFIIS or Rpb9 deletions. TFIIS and Rpb9 are both essential for transcription 
fidelity, so placing our backtrack site mutations in these genetic backgrounds would allow 
us to better elucidate the role of backtracking in transcription fidelity. Furthermore, we 
can mutate other Rpb1 and Rpb2 residues in the backtrack site using similar techniques 
in this study in order to characterize their physiological importance and develop a more 
comprehensive understanding of the backtrack site and its effects on various aspects of 
transcription regulation.   
 Altogether, the importance of backtracking and the precise mechanisms 
underlying this conserved phenomenon remain elusive, but we were able to demonstrate 
that the backtrack site is essential for cell survival and for various aspects of transcription, 
such as fidelity, elongation speed, and termination efficiency in vivo. While our results 
provide some insights into the physiological role of backtracking, more research must be 
done to further elucidate the physiological role of the backtrack site and the importance 
of backtracking. 
 
 
45 
 
GLOSSARY22 
active site:  the region of an enzyme containing the catalytic residues identified with the 
 binding and reaction of substrate(s). 
allele: any of the forms of the same gene that occur at the same place on a homologous 
 chromosome but differ in base sequence. 
amino acid: any organic acid containing one or more amino substituents, a carboxyl 
 group, and a side-chain specific to each amino acid. A table containing all 
 known amino acids is provided in the Appendix (Figure A1).  
annealing: the pairing of complementary sequences of single-stranded DNA or RNA to 
 form a hybrid double‐stranded nucleic acid molecule. 
base pair:  any of the possible pairings between two bases in opposing strands of 
 double‐stranded DNA or RNA molecules. Adenine forms a base pair with 
 thymine (in DNA) or uracil (in RNA) and guanine with cytosine, hence the 
 number of adenine residues equals the number of thymine (and/or uracil) 
 residues while the number of guanine residues equals that of the cytosine 
 residues.  
catalysis: an increase in the rate of a chemical reaction brought about by a catalyst 
 (generally an enzyme in molecular biology).  
conformation: the characteristic 3-dimensional shape of a protein, including the 
 secondary, supersecondary (motifs), tertiary (domains) and quaternary structure 
 of the peptide chain. 
culture: a collection of cells, tissue fragments, or an organ that is growing or being kept 
 alive in or on a nutrient medium.  
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DNA: (contrast with RNA) one of the two main types of nucleic acids consisting of a 
 long, unbranched macromolecule formed from one, or more commonly, two, 
 strands of linked deoxyribonucleotides; self-replicating material which is present 
 in nearly all living organisms serves as the carrier of genetic information.   
enzyme: any naturally occurring or synthetic macromolecular substance composed of 
 protein, that catalyzes, more or less specifically, one or more biochemical 
 reactions. 
eukaryotes: (contrast with prokaryotes) any organism whose cells contain a nucleus 
 enclosed within membranes and undergo meiosis. 
fidelity (of transcription): accuracy of transcription. 
fitness: the survival value and the reproductive capability of a given genotype as 
 compared with the average of the population or of other genotypes in the 
 population. 
gene: the functional unit of heredity consisting of DNA that codes for a protein that 
 performs the functions associated with the phenotypic expression of the gene.  
genome: the whole of the genetic information of an organism. 
homologous: (of sequences of residues in encoded macromolecules) having the same or 
 similar residues at corresponding positions; (of proteins from different species) 
 having identical or similar functions. 
homologous recombination: genetic recombination between two DNA molecules of 
 identical or nearly identical sequence when contained in the same cell. 
in vivo: Latin for “in life”; occurring or made to occur within a living organism.  
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in vitro: Latin for “in the glass”; performed or taking place in a test tube, culture dish, or 
 elsewhere outside a living organism. 
log phase: period when the number of  cells doubles at a constant, exponential rate. 
media: any nutrient medium that is designed to support the growth or maintenance of 
 a culture. Culture media are typically prepared artificially and designed for a 
 specific type of cell, tissue, or organ. They usually consist of a soft gel (so‐ called solid or semisolid medium) or a liquid, but occasionally they are rigid 
 solids. 
messenger RNA: a class of naturally occurring RNA molecules that carry the 
 information embodied in the genes of DNA to the ribosomes, where they direct 
 protein synthesis. 
mutation (of a gene): permanent alteration in the DNA sequence that makes up a gene, 
 such that the sequence differs from what is found in most individuals in a 
 population.  
nascent: just coming into existence; newly synthesized. 
nucleotides: a compound consisting of a nucleoside linked to a phosphate group. 
 Nucleotides form the basic structural unit of the nucleic acids DNA and RNA.  
open reading frame: a sequence in DNA encoding the entire protein that has 
 a length divisible by three and begins with a translation start codon (ATG) and 
 ends at a stop codon. 
optical density: a measure of the turbidity, or density, of liquid cultures of 
 microorganisms.  
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PCR: polymerase chain reaction; method widely used in molecular biology to make 
 many copies of a specific DNA segment.  
phenotype:  the totality of the observable functional and structural characteristics of an 
 organism as determined by interaction of the genotype of the organism with the 
 environment in which it exists. 
plasmid: a genetic structure in a cell that can replicate independently of the 
 chromosomes; typically a small circular DNA strand in the cytoplasm of a 
 bacterium or protozoan.  
polymerase: a general name for any transferase enzyme that catalyses the formation of 
 biological polymers, especially of polynucleotides. 
primer: a short oligonucleotide sequence that provides a starting point for DNA 
 synthesis. 
processivity: the ability of an enzyme ability to catalyze consecutive reactions without 
 releasing its substrate. 
proteome: the entire complement of proteins that is or can be expressed by a cell, tissue, 
 or organism.  
prokaryotes: (contrast with eukaryotes) any organism in which the genomic DNA is not 
 enclosed by a nuclear membrane within the cells. 
residues: any of the incorporated amino acid monomers in a peptide or protein.  
restriction endonucleases: any of a group of enzymes, produced by bacteria, that cleave 
 molecules of DNA internally at specific base sequences. 
RNA: (contrast with DNA) one of the two main types of nucleic acids consisting of a 
 long, unbranched macromolecule formed from ribonucleotides. 
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substrate: a substance that is acted upon, especially by an enzyme; a molecule or 
 structure whose transformation is catalysed by an enzyme. 
subunit: any polypeptide component within a protein. 
transformation: the transfer of genetic information by means of naked extracellular 
 DNA in bacteria. 
translation: the process by which a particular sequence of bases in messenger RNA 
 (mRNA) determines a sequence of amino acids in a polypeptide chain during 
 protein synthesis.  
X-ray crystallography: a technique for determining the three-dimensional structure of 
 molecules, including complex biological macromolecules such as proteins and 
 nucleic acids, by X-ray diffraction.  
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APPENDIX 
Figure A1. The structures, abbreviations, and chemical properties of all amino acids 
(taken from Dan Cojocari, Department of Medical Biophysics, University of Toronto). 
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Figure A2. RPB1 region of TOPO vector encoding residues (bolded) that are proposed 
to contact RNA in the arrested complex (codons for these residues are highlighted in 
green). The XbaI site and residues changed to create the DraIII and BamHI sites are 
depicted (blue) together with wild-type bases that are part of the engineered restriction 
sites (yellow). The residue T831 (pink) is proposed to sense whether the 3’ end of the 
DNA-RNA hybrid is frayed23. The forward primer DHO473 introduces the BamHI site 
and introduces the K752T mutation. The forward primer DHO26 anneals upstream of the 
XbaI site, while the reverse primer DHO436 anneals downstream of the XbaI site.  
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